KRM Ayurveda is going public through an SME IPO to raise Rs 77.49 crore.
The IPO is entirely a fresh issue of 0.57 crore shares, with a price band of Rs 128-135 per share.
IPO Open: January 19, 2026
IPO Close: January 21, 2026
Allotment Date: January 22, 2026 (tentative)
Listing on NSE SME: January 27, 2026 (tentative)
Contents
Objectives of the IPO
The funds raised from this IPO will be used for:
Rs 13.67 crore – Capital expenditure for constructing and developing telemedicine facilities
Rs 22.90 crore – Working capital requirements
Rs 12.50 crore – Repayment of borrowings
This will help KRM Ayurveda expand its services and strengthen its financial position.
Lot Size and Application Details
Retail investors: Minimum 2 lots × 100 shares = Rs 2.70 lakh
HNI investors: Minimum 3 lots × 3,000 shares = Rs 4.05 lakh
Book running lead manager: NEXGEN Financial Solutions
Registrar: Skyline Financial Services
Market Maker: Mansi Share & Stock Broking
About KRM Ayurveda
Founded in 2019, KRM Ayurveda operates hospitals, clinics, and telemedicine services in India and abroad.
The company produces Ayurvedic medicines, herbal remedies, supplements, and wellness products.
Currently, KRM Ayurveda runs:
6 hospitals
5 clinics across India
The company aims to expand its telemedicine and healthcare services using the IPO funds.
Key Risks for Investors
Before investing, here are some important risks to consider:
Leased Premises: Most hospitals and offices are on lease. Renewal of leases isn’t guaranteed, and relocation could disrupt operations.
Revenue Concentration: 68% of income comes from Delhi and Haryana, making the business geographically concentrated.
High Employee Turnover: Employee attrition was 78.47% in FY24, which could affect operations.
Legal Issues: The company and promoters are involved in litigations and consumer complaints, including medical negligence cases.
Dependence on Third-Party Payers: Revenue relies heavily on insurance providers and government health schemes.
Any changes in reimbursements or delays in payments could impact cash flow.
This SME IPO offers an opportunity to invest in Ayurveda healthcare expansion, but potential investors should carefully consider the risks and operational challenges before subscribing.